The Coalition for Epidemic Preparedness Innovations (CEPI) will “urgently accelerate” the development of three investigational vaccines targeting the Bundibugyo virus, responsible for the current Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda, the organisation announced on Monday.
"With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease,” said Dr Richard Hatchett, CEPI’s Chief Executive Officer.
“CEPI’s urgent funding and support for these three promising candidates aims to advance safe, effective vaccines to help control this epidemic.”
CEPI is a global public-private partnership that finances and accelerates the development of vaccines and biological countermeasures against emerging infectious diseases and potential pandemics.
The foundation announced that it will invest in a portfolio of inoculation candidates under development, including those developed by The International AIDS Vaccine Initiative, Moderna and the University of Oxford, which will be manufactured at the Serum Institute of India (SII).
